rediff.com

NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  

Rediff News  All News 
Rediff.com  » Business » Ranbaxy business to be profitable in short term: Sun Pharma

Ranbaxy business to be profitable in short term: Sun Pharma

Last updated on: April 07, 2014 10:16 IST

Sun Pharmaceutical Industries Ltd managing director Dilip Shanghvi said he expects Ranbaxy Laboratories Ltd to become profitable in the short term.

Sun said it will buy Ranbaxy in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker from two firms struggling with quality issues in the lucrative United States market.

Sun plans to focus on remediation of compliance issues that have resulted in bans at multiple Ranbaxy plants, Shanghvi told analysts on a conference call.

Ranbaxy's underlying business has "robust growth," and profitability potential, based on which the price Sun is paying for the deal is "justified," Shanghvi said.

The managing director also said Sun would continue to look for acquisition opportunities even after the Ranbaxy acquisition.

(Reporting by Zeba Siddiqui)

Source:
© Copyright 2013 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.